Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Aim of this study is to evaluate in a population of old osteoporotic chronic kidney disease
females the effect of denosumab:
- on bone mineral density (femoral T-score) at 24 months
- on bone mineral density evolution (femoral T-score) after 24 months of follow-up
- on bone mineral density evolution (lumbar T-score) after 24 months of follow-up
- on coronary and abdominal aorta calcification scores evolution after 24 months of
follow-up
- on parameters of bone remodelling (OPG, RANKL, sclerostin, DKK-1), of mineral and
calcium metabolism (FGF23 Ct, Klotho, PTH, 25(OH) vitamin D3, phosphorus, calcium, bone
alklaline phosphatase, osteocalcin, CTX), of inflammation (CRP) after 24 months of
follow-up
- on cardiovascular morbidity (cardiovascular events) and mortality after 24 months of
follow-up
- the tolerance after 24 months of follow-up